-
1
-
-
42249083269
-
Weekly paclitaxel in the adjuvant treatment of breast cancer
-
DOI 10.1056/NEJMoa0707056
-
Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. The New England journal of medicine. 2008;358:1663-71. (Pubitemid 351549913)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.16
, pp. 1663-1671
-
-
Sparano, J.A.1
Wang, M.2
Martino, S.3
Jones, V.4
Perez, E.A.5
Saphner, T.6
Wolff, A.C.7
Sledge Jr., G.W.8
Wood, W.C.9
Davidson, N.E.10
-
2
-
-
70349260426
-
Single agent versus combination chemotherapy for metastatic breast cancer
-
Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009;CD003372
-
(2009)
Cochrane Database Syst Rev.
-
-
Carrick, S.1
Parker, S.2
Thornton, C.E.3
Ghersi, D.4
Simes, J.5
Wilcken, N.6
-
3
-
-
76749156249
-
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study
-
10.1200/JCO.2008.20.5013 1:CAS:528:DC%2BD1MXhtlCns77I Demonstrated cardiac safety for pegylated liposomal doxorubicin after previous exposure to adjuvant anthracycline therapy
-
Sparano JA, Makhson AN, Semiglazov VF. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009;27:4522-9. Demonstrated cardiac safety for pegylated liposomal doxorubicin after previous exposure to adjuvant anthracycline therapy.
-
(2009)
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
, vol.27
, pp. 4522-4529
-
-
Sparano, J.A.1
Makhson, A.N.2
Semiglazov, V.F.3
-
4
-
-
0032787785
-
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
-
Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999;17:2341-54. (Pubitemid 29368232)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.8
, pp. 2341-2354
-
-
Chan, S.1
Friedrichs, K.2
Noel, D.3
Pinter, T.4
Van Belle, S.5
Vorobiof, D.6
Duarte, R.7
Gil, M.G.8
Bodrogi, I.9
Murray, E.10
Yelle, L.11
Von Minckwitz, G.12
Korec, S.13
Simmonds, P.14
Buzzi, F.15
Gonzalez Mancha, R.16
Richardson, G.17
Walpole, E.18
Ronzoni, M.19
Murawsky, M.20
Alakl, M.21
Riva, A.22
Crown, J.23
more..
-
5
-
-
0037441856
-
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An Intergroup trial (E1193)
-
DOI 10.1200/JCO.2003.08.013
-
Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21:588-92. (Pubitemid 46621890)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.4
, pp. 588-592
-
-
Sledge, G.W.1
Neuberg, D.2
Bernardo, P.3
Ingle, J.N.4
Martino, S.5
Rowinsky, E.K.6
Wood, W.C.7
-
6
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2
-
DOI 10.1056/NEJM200103153441101
-
•• Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England journal of medicine. 2001;344:783-92. Demonstrated that trastuzumab improves survival when added to chemotherapy as first-line therapy for HER2/neu overexpression metastatic breast cancer. (Pubitemid 32222155)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
7
-
-
0021070147
-
Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: Preliminary report of a randomized study
-
6365209 10.1007/BF01807589 1:STN:280:DyaL2c7ivV2lsA%3D%3D
-
Kardinal CG, Perry MC, Weinberg V, Wood W, Ginsberg S, Raju RN. Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: preliminary report of a randomized study. Breast Cancer Res Treat. 1983;3:365-71.
-
(1983)
Breast Cancer Res Treat
, vol.3
, pp. 365-371
-
-
Kardinal, C.G.1
Perry, M.C.2
Weinberg, V.3
Wood, W.4
Ginsberg, S.5
Raju, R.N.6
-
8
-
-
84863707351
-
Cancer treatment and survivorship statistics, 2012
-
22700443 10.3322/caac.21149
-
Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220-41.
-
(2012)
CA Cancer J Clin
, vol.62
, pp. 220-241
-
-
Siegel, R.1
Desantis, C.2
Virgo, K.3
-
9
-
-
0036307010
-
Second and subsequent lines of chemotherapy for metastatic breast cancer: What did we learn in the last two decades?
-
DOI 10.1093/annonc/mdf101
-
Cardoso F, Di LA, Lohrisch C, Bernard C, Ferreira F, Piccart MJ. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol. 2002;13:197-207. (Pubitemid 34704970)
-
(2002)
Annals of Oncology
, vol.13
, Issue.2
, pp. 197-207
-
-
Cardoso, F.1
Di Leo, A.2
Lohrisch, C.3
Bernard, C.4
Ferreira, F.5
Piccart, M.J.6
-
10
-
-
31444447160
-
Extending survival with chemotherapy in metastatic breast cancer
-
DOI 10.1634/theoncologist.10-90003-20
-
O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10 Suppl 3:20-9. (Pubitemid 43152727)
-
(2005)
Oncologist
, vol.10
, Issue.SUPPL.. 3
, pp. 20-29
-
-
O'Shaughnessy, J.1
-
11
-
-
0029789811
-
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
-
Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197-205. (Pubitemid 26264869)
-
(1996)
Journal of Clinical Oncology
, vol.14
, Issue.8
, pp. 2197-2205
-
-
Greenberg, P.A.C.1
Hortobagyi, G.N.2
Smith, T.L.3
Ziegler, L.D.4
Frye, D.K.5
Buzdar, A.U.6
-
12
-
-
0032949449
-
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
-
Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1999;17:1413-24. (Pubitemid 29220847)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.5
, pp. 1413-1424
-
-
Nabholtz, J.-M.1
Senn, H.J.2
Bezwoda, W.R.3
Melnychuk, D.4
Deschenes, L.5
Douma, J.6
Vandenberg, T.A.7
Rapoport, B.8
Rosso, R.9
Trillet-Lenoir, V.10
Drbal, J.11
Molino, A.12
Nortier, J.W.R.13
Richel, D.J.14
Nagykalnai, T.15
Siedlecki, P.16
Wilking, N.17
Genot, J.Y.18
Hupperets, P.S.G.J.19
Pannuti, F.20
Skarlos, D.21
Tomiak, E.M.22
Murawsky, M.23
Alakl, M.24
Riva, A.25
Aapro, M.26
more..
-
13
-
-
79952487463
-
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study
-
21376385 10.1016/S0140-6736(11)60070-6 1:CAS:528:DC%2BC3MXjtFWgs7c%3D Demonstrated that eribulin improved survival compared with physician's choice of another monotherapy regimen for patients with extensively pretreated metastatic breast cancer
-
•• Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914-23. Demonstrated that eribulin improved survival compared with physician's choice of another monotherapy regimen for patients with extensively pretreated metastatic breast cancer.
-
(2011)
Lancet
, vol.377
, pp. 914-923
-
-
Cortes, J.1
O'Shaughnessy, J.2
Loesch, D.3
-
14
-
-
0037096755
-
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results
-
DOI 10.1200/JCO.2002.09.002
-
O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002;20:2812-23. (Pubitemid 34651510)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.12
, pp. 2812-2823
-
-
O'Shaughnessy, J.1
Miles, D.2
Vukelia, S.3
Moiseyenko, V.4
Ayoub, J.-P.5
Cervantes, G.6
Fumoleau, P.7
Jones, S.8
Lui, W.-Y.9
Mauriac, L.10
Twelves, C.11
Van Hazel, G.12
Verma, S.13
Leonard, R.14
-
15
-
-
0346847742
-
Is Breast Cancer Survival Improving? Trends in Survival for Patients with Recurrent Breast Cancer Diagnosed from 1974 through 2000
-
DOI 10.1002/cncr.11859
-
Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100:44-52. (Pubitemid 37553538)
-
(2004)
Cancer
, vol.100
, Issue.1
, pp. 44-52
-
-
Giordano, S.H.1
Buzdar, A.U.2
Smith, T.L.3
Kau, S.-W.4
Yang, Y.5
Hortobagyi, G.N.6
-
16
-
-
34548187711
-
The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer
-
DOI 10.1002/cncr.22867
-
Chia SK, Speers CH, D'Yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973-9. (Pubitemid 47312861)
-
(2007)
Cancer
, vol.110
, Issue.5
, pp. 973-979
-
-
Chia, S.K.1
Speers, C.H.2
D'Yachkova, Y.3
Kang, A.4
Malfair-Taylor, S.5
Barnett, J.6
Coldman, A.7
Gelmon, K.A.8
O'Reilly, S.E.9
Olivotto, I.A.10
-
17
-
-
54449095991
-
Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer
-
10.1200/JCO.2007.14.1168
-
Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008;26:4891-8.
-
(2008)
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
, vol.26
, pp. 4891-4898
-
-
Dawood, S.1
Broglio, K.2
Gonzalez-Angulo, A.M.3
Buzdar, A.U.4
Hortobagyi, G.N.5
Giordano, S.H.6
-
18
-
-
84874672704
-
Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years
-
Tevaarwerk AJ, Gray RJ, Schneider BP, et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: Little evidence of improvement over the past 30 years. Cancer 2012
-
(2012)
Cancer
-
-
Tevaarwerk, A.J.1
Gray, R.J.2
Schneider, B.P.3
-
19
-
-
36849071808
-
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
-
DOI 10.1200/JCO.2007.12.6557
-
Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210-7. (Pubitemid 350232252)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.33
, pp. 5210-5217
-
-
Thomas, E.S.1
Gomez, H.L.2
Li, R.K.3
Chung, H.-C.4
Fein, L.E.5
Chan, V.F.6
Jassem, J.7
Pivot, X.B.8
Klimovsky, J.V.9
De Mendoza, F.H.10
Xu, B.11
Campone, M.12
Lerzo, G.L.13
Peck, R.A.14
Mukhopadhyay, P.15
Vahdat, L.T.16
Roche, H.H.17
-
20
-
-
77954752064
-
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
-
10.1200/JCO.2009.24.4244 1:CAS:528:DC%2BC3cXhtVajur3E Phase III trial which showed that the ixabepilone-capecitabine combination improved response and progression-free survival compared with capecitabine alone for anthracycline and taxane-pretreated breast cancer; the combination did not improve survival
-
•• Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28:3256-63. Phase III trial which showed that the ixabepilone-capecitabine combination improved response and progression-free survival compared with capecitabine alone for anthracycline and taxane-pretreated breast cancer; the combination did not improve survival.
-
(2010)
Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
, vol.28
, pp. 3256-3263
-
-
Sparano, J.A.1
Vrdoljak, E.2
Rixe, O.3
-
21
-
-
0033953330
-
A unified definition of clinical anthracycline resistance breast cancer
-
Pivot X, Asmar L, Buzdar AU, Valero V, Hortobagyi G. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer. 2000;82:529-34. Proposed definitions for anthracycine and taxane pretreatment versus resistance. (Pubitemid 30085185)
-
(2000)
British Journal of Cancer
, vol.82
, Issue.3
, pp. 529-534
-
-
Pivot, X.1
Asmar, L.2
Buzdar, A.U.3
Valero, V.4
Hortobagyi, G.5
-
22
-
-
0031415404
-
Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy
-
DOI 10.1016/S0959-8049(97)10011-9, PII S0959804997100119
-
Castiglione-Gertsch M, Tattersall M, Hacking A, et al. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The international breast cancer study group. Eur J Cancer. 1997;33:2321-5. (Pubitemid 28129170)
-
(1997)
European Journal of Cancer
, vol.33
, Issue.14
, pp. 2321-2325
-
-
Castiglione-Gertsch, M.1
Tattersall, M.2
Hacking, A.3
Goldhirsch, A.4
Gudgeon, A.5
Gelber, R.D.6
Lindtner, J.7
Coates, A.8
Collins, J.9
Isley, M.10
Senn, H.-J.11
Rudenstam, C.-M.12
-
23
-
-
80052908255
-
Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy
-
10.1159/000327515
-
Guo X, Loibl S, Untch M, et al. Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy. Breast Care (Basel). 2011;6:279-83.
-
(2011)
Breast Care (Basel)
, vol.6
, pp. 279-283
-
-
Guo, X.1
Loibl, S.2
Untch, M.3
-
24
-
-
13644254794
-
Molecular mechanisms of drug resistance
-
DOI 10.1002/path.1706
-
Longley DB, Johnston PG. Molecular mechanisms of drug resistance. The Journal of pathology. 2005;205:275-92. (Pubitemid 40227997)
-
(2005)
Journal of Pathology
, vol.205
, Issue.2
, pp. 275-292
-
-
Longley, D.B.1
Johnston, P.G.2
-
25
-
-
36049029703
-
The role of efflux pumps in drug-resistant metastatic breast cancer: New insights and treatment strategies
-
Fojo T, Coley HM. The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies. Clin Breast Cancer. 2007;7:749-56. (Pubitemid 350086119)
-
(2007)
Clinical Breast Cancer
, vol.7
, Issue.10
, pp. 749-756
-
-
Fojo, T.1
Coley, H.M.2
-
26
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
DOI 10.1056/NEJMoa064320
-
Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-43. (Pubitemid 46021510)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.26
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
Chan, S.4
Romieu, C.G.5
Pienkowski, T.6
Jagiello-Gruszfeld, A.7
Crown, J.8
Chan, A.9
Kaufman, B.10
Skarlos, D.11
Campone, M.12
Davidson, N.13
Berger, M.14
Oliva, C.15
Rubin, S.D.16
Stein, S.17
Cameron, D.18
-
27
-
-
0035476911
-
Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients
-
DOI 10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A
-
•• Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92:1759-68. Demonstrated efficacy of capecitabine monotherapy for anthracycline and taxane-pretreated metastatic breast cancer. (Pubitemid 32952493)
-
(2001)
Cancer
, vol.92
, Issue.7
, pp. 1759-1768
-
-
Blum, J.L.1
Dieras, V.2
Russo, P.M.L.3
Horton, J.4
Rutman, O.5
Buzdar, A.6
Osterwalder, B.7
-
28
-
-
20244368234
-
Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women
-
DOI 10.1200/JCO.2005.02.167
-
Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol. 2005;23:2155-61. (Pubitemid 46218707)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.10
, pp. 2155-2161
-
-
Bajetta, E.1
Procopio, G.2
Celio, L.3
Gattinoni, L.4
Della Torre, S.5
Mariani, L.6
Catena, L.7
Ricotta, R.8
Longarini, R.9
Zilembo, N.10
Buzzoni, R.11
-
29
-
-
42949171085
-
Phase i study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer
-
18398145 10.1200/JCO.2007.13.8388 1:CAS:528:DC%2BD1cXmsFemsLc%3D
-
Traina TA, Theodoulou M, Feigin K, et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol. 2008;26:1797-802.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1797-1802
-
-
Traina, T.A.1
Theodoulou, M.2
Feigin, K.3
-
30
-
-
20044364346
-
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
-
DOI 10.1200/JCO.2005.05.098
-
Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-9. (Pubitemid 46224178)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.4
, pp. 792-799
-
-
Miller, K.D.1
Chap, L.I.2
Holmes, F.A.3
Cobleigh, M.A.4
Marcom, P.K.5
Fehrenbacher, L.6
Dickler, M.7
Overmoyer, B.A.8
Reimann, J.D.9
Sing, A.P.10
Langmuir, V.11
Rugo, H.S.12
-
31
-
-
0034895987
-
BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy
-
Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7:1429-37. (Pubitemid 32708699)
-
(2001)
Clinical Cancer Research
, vol.7
, Issue.5
, pp. 1429-1437
-
-
Lee, F.Y.F.1
Borzilleri, R.2
Fairchild, C.R.3
Kim, S.-H.4
Long, B.H.5
Reventos-Suarez, C.6
Vite, G.D.7
Rose, W.C.8
Kramer, R.A.9
-
32
-
-
3042701597
-
Epothilones: Mechanism of action and biologic activity
-
DOI 10.1200/JCO.2004.12.001
-
Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol. 2004;22:2015-25. (Pubitemid 41095195)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.10
, pp. 2015-2025
-
-
Goodin, S.1
Kane, M.P.2
Rubin, E.H.3
-
33
-
-
34548157209
-
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine
-
DOI 10.1200/JCO.2006.09.3849
-
Perez EA, Lerzo G, Pivot X, et al. Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine. J Clin Oncol. 2007;25:3407-14. (Pubitemid 47310876)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.23
, pp. 3407-3414
-
-
Perez, E.A.1
Lerzo, G.2
Pivot, X.3
Thomas, E.4
Vahdat, L.5
Bosserman, L.6
Viens, P.7
Cai, C.8
Mullaney, B.9
Peck, R.10
Hortobagyi, G.N.11
-
34
-
-
79251530503
-
Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: A pooled analysis by performance status of efficacy and safety data from 2 phase III studies
-
21128114 10.1007/s10549-010-1251-y 1:CAS:528:DC%2BC3MXhtVelsLk%3D Pooled analysis of 2 phase III trials indicating a survival benefit of the ixabepilone-capecitabine combination compared with capecitabine alone for patients with a Karnofsky performance status of 70-80, but not 90-100
-
Roche H, Conte P, Perez EA, et al. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: A pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast cancer research and treatment. 2011;125:755-65. Pooled analysis of 2 phase III trials indicating a survival benefit of the ixabepilone-capecitabine combination compared with capecitabine alone for patients with a Karnofsky performance status of 70-80, but not 90-100.
-
(2011)
Breast Cancer Research and Treatment
, vol.125
, pp. 755-765
-
-
Roche, H.1
Conte, P.2
Perez, E.A.3
-
35
-
-
78751525051
-
Eribulin induces irreversible mitotic blockade: Implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions
-
21127197 10.1158/0008-5472.CAN-10-1874 1:CAS:528:DC%2BC3MXlsFKlsA%3D%3D
-
Towle MJ, Salvato KA, Wels BF, et al. Eribulin induces irreversible mitotic blockade: Implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011;71:496-505.
-
(2011)
Cancer Res
, vol.71
, pp. 496-505
-
-
Towle, M.J.1
Salvato, K.A.2
Wels, B.F.3
-
36
-
-
67649908927
-
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
-
19349550 10.1200/JCO.2008.17.7618 1:CAS:528:DC%2BD1MXoslyis74%3D
-
Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009;27:2954-61.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2954-2961
-
-
Vahdat, L.T.1
Pruitt, B.2
Fabian, C.J.3
-
37
-
-
77957594393
-
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
-
20679609 10.1200/JCO.2009.25.8467 1:CAS:528:DC%2BC3cXht1eqsbzM
-
Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010;28:3922-8.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3922-3928
-
-
Cortes, J.1
Vahdat, L.2
Blum, J.L.3
-
38
-
-
84861733607
-
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer
-
21989327 10.1093/annonc/mdr444 1:STN:280:DC%2BC38zmsVSrtw%3D%3D
-
Aogi K, Iwata H, Masuda N, et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2012;23:1441-8.
-
(2012)
Ann Oncol
, vol.23
, pp. 1441-1448
-
-
Aogi, K.1
Iwata, H.2
Masuda, N.3
-
39
-
-
84873470069
-
-
Eribulin301. http://www.eisai.com/news/enews201244pdf.pdf. 2012
-
(2012)
Eribulin301
-
-
-
40
-
-
0028799108
-
Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
-
7481842 1:CAS:528:DyaK2MXpsFGntbY%3D
-
Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22:3-10.
-
(1995)
Semin Oncol
, vol.22
, pp. 3-10
-
-
Plunkett, W.1
Huang, P.2
Xu, Y.Z.3
Heinemann, V.4
Grunewald, R.5
Gandhi, V.6
-
41
-
-
33847138943
-
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: Final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial
-
DOI 10.1016/S1470-2045(07)70041-4, PII S1470204507700414
-
Martin M, Ruiz A, Munoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007;8:219-25. (Pubitemid 46291704)
-
(2007)
Lancet Oncology
, vol.8
, Issue.3
, pp. 219-225
-
-
Martin, M.1
Ruiz, A.2
Munoz, M.3
Balil, A.4
Garcia-Mata, J.5
Calvo, L.6
Carrasco, E.7
Mahillo, E.8
Casado, A.9
Garcia-Saenz, J.A.10
Escudero, M.J.11
Guillem, V.12
Jara, C.13
Ribelles, N.14
Salas, F.15
Soto, C.16
Morales-Vasquez, F.17
Rodriguez, C.A.18
Adrover, E.19
Mel, J.R.20
more..
-
42
-
-
0032947768
-
Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
-
Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17:409-22. (Pubitemid 29022420)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.1
, pp. 409-422
-
-
Go, R.S.1
Adjei, A.A.2
-
43
-
-
78649663174
-
BRCA mutations in the management of breast cancer: The state of the art
-
20956982 10.1038/nrclinonc.2010.166 1:CAS:528:DC%2BC3cXhsVygtr3E
-
Narod SA. BRCA mutations in the management of breast cancer: The state of the art. Nat Rev Clin Oncol. 2010;7:702-7.
-
(2010)
Nat Rev Clin Oncol
, vol.7
, pp. 702-707
-
-
Narod, S.A.1
-
44
-
-
1242329822
-
Platinum-based chemotherapy in metastatic breast cancer: Current status
-
DOI 10.1016/S0305-7372(03)00139-7
-
Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: Current status. Cancer Treat Rev. 2004;30:53-81. (Pubitemid 38240088)
-
(2004)
Cancer Treatment Reviews
, vol.30
, Issue.1
, pp. 53-81
-
-
Decatris, M.P.1
Sundar, S.2
O'Byrne, K.J.3
-
46
-
-
78751610848
-
Iniparib plus chemotherapy in metastatic triple-negative breast cancer
-
21208101 10.1056/NEJMoa1011418
-
O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364:205-14.
-
(2011)
N Engl J Med
, vol.364
, pp. 205-214
-
-
O'Shaughnessy, J.1
Osborne, C.2
Pippen, J.E.3
-
47
-
-
84859202634
-
Drug candidates derailed in case of mistaken identity
-
22460874 10.1038/483519a 1:CAS:528:DC%2BC38Xks12huro%3D
-
Ledford H. Drug candidates derailed in case of mistaken identity. Nature. 2012;483:519.
-
(2012)
Nature
, vol.483
, pp. 519
-
-
Ledford, H.1
-
48
-
-
0034509633
-
Mechanism of action of camptothecin
-
Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP. Mechanism of action of camptothecin. Ann N Y Acad Sci. 2000;922:1-10. (Pubitemid 32050237)
-
(2000)
Annals of the New York Academy of Sciences
, vol.922
, pp. 1-10
-
-
Liu, L.F.1
Desai, S.D.2
Li, T.-K.3
Mao, Y.4
Sun, M.5
Sim, S.-P.6
-
49
-
-
4344695312
-
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both
-
DOI 10.1200/JCO.2004.10.047
-
Perez EA, Hillman DW, Mailliard JA, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol. 2004;22:2849-55. Demonstrated efficacy of irinotecan for patients with extensively pretreated metastatic breast cancer. (Pubitemid 41079903)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.14
, pp. 2849-2855
-
-
Perez, E.A.1
Hillman, D.W.2
Mailliard, J.A.3
Ingle, J.N.4
Ryan, J.M.5
Fitch, T.R.6
Rowland, K.M.7
Kardinal, C.G.8
Krook, J.E.9
Kugler, J.W.10
Dakhil, S.R.11
-
50
-
-
77749264641
-
28th Annual JPMorgan Healthcare Conference - Exelixis and Nektar Therapeutics
-
20191424
-
Gale S, Croasdell G. 28th Annual JPMorgan Healthcare Conference - Exelixis and Nektar Therapeutics. IDrugs. 2010;13:139-41.
-
(2010)
IDrugs
, vol.13
, pp. 139-141
-
-
Gale, S.1
Croasdell, G.2
-
51
-
-
0000631893
-
Negative Staining of Phospholipids and Their Structural Modification by Surface-Active Agents as Observed in the Electron Microscope
-
14187392 10.1016/S0022-2836(64)80115-7 1:CAS:528:DyaF2cXktlers70%3D
-
Bangham AD, Horne RW. Negative Staining of Phospholipids and Their Structural Modification by Surface-Active Agents as Observed in the Electron Microscope. J Mol Biol. 1964;8:660-8.
-
(1964)
J Mol Biol
, vol.8
, pp. 660-668
-
-
Bangham, A.D.1
Horne, R.W.2
-
52
-
-
0027299669
-
Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): Comparison with doxorubicin and empty liposomes in mice and dogs
-
Kanter PM, Bullard GA, Pilkiewicz FG, Mayer LD, Cullis PR, Pavelic ZP. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo. 1993;7:85-95. (Pubitemid 23156481)
-
(1993)
In Vivo
, vol.7
, Issue.1
, pp. 85-95
-
-
Kanter, P.M.1
Bullard, G.A.2
Pilkiewicz, F.G.3
Mayer, L.D.4
Cullis, P.R.5
Pavelic, Z.P.6
-
53
-
-
0027314129
-
Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs
-
Kanter PM, Bullard GA, Ginsberg RA, et al. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo. 1993;7:17-26. (Pubitemid 23156471)
-
(1993)
In Vivo
, vol.7
, Issue.1
, pp. 17-26
-
-
Kanter, P.M.1
Bullard, G.A.2
Ginsberg, R.A.3
Pilkiewicz, F.G.4
Mayer, L.D.5
Cullis, P.R.6
Pavelic, Z.P.7
-
54
-
-
0037681850
-
Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies
-
DOI 10.2165/00003088-200342050-00002
-
Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42:419-36. (Pubitemid 36649037)
-
(2003)
Clinical Pharmacokinetics
, vol.42
, Issue.5
, pp. 419-436
-
-
Gabizon, A.1
Shmeeda, H.2
Barenholz, Y.3
-
55
-
-
19944396126
-
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
-
DOI 10.1053/j.seminoncol.2004.09.018, PII S0093775404004154
-
Robert NJ, Vogel CL, Henderson IC, et al. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol. 2004;31:106-46. (Pubitemid 40023244)
-
(2004)
Seminars in Oncology
, vol.31
, Issue.SUPPL.. 13
, pp. 106-146
-
-
Robert, N.J.1
Vogel, C.L.2
Henderson, I.C.3
Sparano, J.A.4
Moore, M.R.5
Silverman, P.6
Overmoyer, B.A.7
Shapiro, C.L.8
Park, J.W.9
Colbern, G.T.10
Winer, E.P.11
Gabizon, A.A.12
-
56
-
-
5444251223
-
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer
-
DOI 10.1200/JCO.2004.08.157
-
Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol. 2004;22:3893-901. (Pubitemid 41079870)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.19
, pp. 3893-3901
-
-
Keller, A.M.1
Mennel, R.G.2
Georgoulias, V.A.3
Nabholtz, J.-M.4
Erazo, A.5
Lluch, A.6
Vogel, C.L.7
Kaufmann, M.8
Von Minckwitz, G.9
Henderson, I.C.10
Mellars, L.11
Alland, L.12
Tendler, C.13
|